Publikationen in Zusammenarbeit mit Forschern von Universitat de Barcelona (18)

2024

  1. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

2021

  1. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

    Nature Communications, Vol. 12, Núm. 1

2020

  1. 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis

    Journal of medicinal chemistry, Vol. 63, Núm. 17, pp. 9237-9257

2019

  1. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease

    Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910

2018

  1. Development and Validation of Molecular Overlays Derived from Three-Dimensional Hydrophobic Similarity with PharmScreen

    Journal of Chemical Information and Modeling, Vol. 58, Núm. 8, pp. 1596-1609

2017

  1. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice

    Neuropsychopharmacology, Vol. 42, Núm. 2, pp. 524-539

  2. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors

    Frontiers in Pharmacology, Vol. 8, Núm. OCT

  3. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8

  4. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332

  5. Information retrieval and text mining technologies for chemistry

    Chemical Reviews, Vol. 117, Núm. 12, pp. 7673-7761

2016

  1. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels

    Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415

  2. Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay

    Journal of Pharmacology and Experimental Therapeutics, Vol. 358, Núm. 3, pp. 580-587

2015

  1. Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease

    Clinical Epigenetics, Vol. 7, Núm. 1

  2. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

    Neuropathology and Applied Neurobiology, Vol. 41, Núm. 4, pp. 471-482

2014

  1. Phosphodiesterase inhibition in cognitive decline

    Journal of Alzheimer's Disease, Vol. 42, pp. S561-S573

  2. The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model

    Neurobiology of Aging, Vol. 35, Núm. 11, pp. 2603-2616

2013

  1. Epigenetic drugs in Alzheimer's disease

    Biomolecular Concepts, Vol. 4, Núm. 5, pp. 443-445

  2. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD

    Neuropharmacology, Vol. 64, pp. 114-123